Through a kinome-centered CRISPR-Cas9 screen in CWR-R1 prostate cancer cells, scientists identified activated BRAF signaling as a determinant for enzalutamide resistance.
[Scientific Reports]
Sorry, but the selected Zotpress account can't be found.
